ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection

Andreoné, Pietro; Colombo, Massimo; Enejosa, Jeffrey; Köksal, İftihar; Ferenci, Péter; Maieron, A; Müllhaupt, Beat; Horsmans, Yves; Weiland, Ola; W. Reesink, H.; Rodrigues, Lino; Hu, Yiran; Podsadecki, Thomas; Bernstein, Barry

doi:10.1053/j.gastro.2014.04.045

Public

ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection

Published in Gastroenterology • May 9, 2014

Authors:

Pietro Andreoné

Massimo Colombo

Jeffrey Enejosa

Abstract

BACKGROUND & AIMS: The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside polymerase inhibitor), and ribavirin has shown efficacy in patients with hepatitis C virus (HCV) genotype 1b infection-the most prevalent subgenoty...

Subject

Ombitasvir

Dasabuvir

Paritaprevir

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!